TACSTD2 and cancer: Our primary objective was to assess the feasibility of 68Ga-MY6349 PET/CT imaging for the noninvasive assessment of Trop2 expression in various cancer types, promoting precision therapy of Trop2-targeted ADCs, and expand future application.